Injectable division
Retatrutide
AClass-leading
Eli Lilly · certified
vs
Injectable division
Semaglutide 2.4 mg (Wegovy)
CompetitiveB
Novo Nordisk · approved
21% · leads
Efficacy
12%
Notable (+6.4)
Tolerability
gentler · Mild (+3.9)
Subcutaneous injection
Route
Subcutaneous injection
None
Food / water rule
None
Refrigerated
Storage
Refrigerated (room temperature up to 28 days)
The call: Retatrutide leads on efficacy: class leading to Semaglutide 2.4 mg's competitive (21% vs 12%). Semaglutide 2.4 mg is the easier of the two to stay on (Mild vs Notable). The caveat that changes the verdict: Retatrutide's edge rests on a number that is topline, not yet peer-reviewed and not yet approved, while Semaglutide 2.4 mg's is published and easier to stay on. Until it is confirmed, the confident pick is Semaglutide 2.4 mg.
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Winners are called only across a tier or band boundary; within one, the drugs are effectively tied. The side marked leads or gentler wins that axis.
Retatrutide verdict · Semaglutide 2.4 mg verdict · How this is scored